C. DeVane

J. Donovan, J. Markowitz, C. DeVane, 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Excessive plasma concentration of tricyclic antidepressants resulting from usual doses: a report of six cases.

C. DeVane, W. Jusko, T. Sutfin, 1981, Journal of Clinical Psychiatry.

Plasma Concentration Monitoring of Hydroxylated Metabolites of Imipramine and Desipramine

W J Jusko, C L DeVane, C. DeVane, 1981, Drug intelligence & clinical pharmacy.

Differential Time Course of Cytochrome P450 2D6 Enzyme Inhibition by Fluoxetine, Sertraline, and Paroxetine in Healthy Volunteers

S. Risch, J. Markowitz, C. DeVane, 2002, Journal of clinical psychopharmacology.

Pro-inflammatory biomakers in depression: Treatment with venlafaxine

J. Sinacore, J. Piletz, C. DeVane, 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Marijuana Use in America: Whither Are We Bound?

C. DeVane, 2013, Pharmacotherapy.

Drug interactions with psychostimulants.

J. Markowitz, C. DeVane, S. D. Morrison, 1999, International clinical psychopharmacology.

Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.

S. Risch, J. Markowitz, C. DeVane, 2000, Journal of clinical psychopharmacology.

Antidepressant–Drug Interactions are Potentially but Rarely Clinically Significant

C. DeVane, C. Devane, 2006, Neuropsychopharmacology.

Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence.

S. Sonne, N. Baker, C. DeVane, 2015, Journal of substance abuse treatment.

Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.

C. DeVane, 2003, The Journal of clinical psychiatry.

Measurement of haloperidol and reduced haloperidol in human plasma using reversed-phase high-performance liquid chromatography.

C. DeVane, R. Miller, 1986, Journal of chromatography.

Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.

Z. Nahas, M. Horner, S. McGurk, 2006, The international journal of neuropsychopharmacology.

A Double-blind Placebo-controlled Case Study of the Use of Donepezil to Improve Cognition in a Schizoaffective Disorder Patient: Functional MRI Correlates.

C L DeVane, Z. Nahas, M. George, 2001, Neurocase.

Pharmacokinetic considerations of antidepressant use in the elderly.

B. Pollock, C. DeVane, 1999, The Journal of clinical psychiatry.

Clinical Pharmacokinetics and Pharmacodynamics of Anxiolytics and Sedative/Hypnotics

C. DeVane, C. Devane, 2016 .

Fluoroquinolone inhibition of clozapine metabolism.

J. Mintzer, J. Markowitz, C. DeVane, 1997, The American journal of psychiatry.

Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

K. Brady, T. Killeen, N. Baker, 2015, Drug and alcohol dependence.

Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

J. Markowitz, C. DeVane, K. Patrick, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

One step purification of alpha(1)-acid glycoprotein from human plasma. Fractionation of its polymorphic allele products.

P. Arnaud, D. Atchley, C. DeVane, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Drug and metabolite concentrations combined in predicting steady-state concentrations from test doses.

C. DeVane, W. Jusko, 1983, Biopharmaceutics & drug disposition.

Effect of bupropion on immunodensity of putative imidazoline receptors on platelets of depressed patients.

D. Reis, J. Piletz, C. DeVane, 1999, Journal of psychiatric research.

Nitric oxide branch of arginine metabolism in depression: effect of venlafaxine.

J. Sinacore, J. Piletz, C. DeVane, 2009 .

Modafinil and Cocaine Interactions

R. Woolson, J. Donovan, S. Hedden, 2006, The American journal of drug and alcohol abuse.

Open‐label steady‐state pharmacokinetic drug interaction study on co‐administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder

D. J. Ennis, C. DeVane, J. Hamer-Maansson, 2007, Human psychopharmacology.

A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology.

J. Donovan, C. DeVane, 2001, Psychopharmacology bulletin.

Antidepressants in amniotic fluid: another route of fetal exposure.

M. Owens, C. DeVane, D. Newport, 2006, The American journal of psychiatry.

The Strategic Plan of the American College of Clinical Pharmacy 1998–2000

J. Powell, D. Covey, K. Lake, 1998, Pharmacotherapy.

INVOLVEMENT OF CYP 3 A 4 , CYP 2 C 8 , AND CYP 2 D 6 IN THE METABOLISM OF ( R )-AND ( S )-METHADONE IN VITRO

C. DeVane, Jun-sheng Wang, 2003 .

What evidence is required for drug exposure to be causally associated with adverse events? The case for case reports published in Pharmacotherapy.

C. DeVane, 2013, Pharmacotherapy.

THE ROLE OF THE POLYMORPHIC EFFLUX TRANSPORTER P-GLYCOPROTEIN ON THE BRAIN ACCUMULATION OF d-METHYLPHENIDATE AND d-AMPHETAMINE

J. Donovan, J. Markowitz, C. DeVane, 2006, Drug Metabolism and Disposition.

Disposition of cocaine in pregnant sheep. I. Pharmacokinetics.

R. Miller, C. DeVane, R. Abrams, 1991, Developmental pharmacology and therapeutics.

Fetoplacental growth and placental protein synthesis in rats after chronic maternal cocaine administration.

I. Tebbett, C. DeVane, K. Shiverick, 1994, Journal of Pharmacology and Experimental Therapeutics.

Tissue distribution of cocaine in the pregnant rat.

J. Simpkins, R. Miller, C. DeVane, 1989, Life sciences.

Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.

C. DeVane, H. Gill, 1997, The Journal of clinical psychiatry.

Use of Psychoactive Drugs in Children

C. DeVane, K. Ahsanuddin, 1983, Drug intelligence & clinical pharmacy.

The analysis and disposition of imipramine and its active metabolites in man

W. Jusko, C. DeVane, T. Sutfin, 1984, Psychopharmacology.

Fundamentals of Monitoring Psychoactive Drug Therapy

C. DeVane, 1990 .

Pharmacology of antidepressants: focus on nefazodone.

C. DeVane, D. Grothe, S. Smith, 2002, The Journal of clinical psychiatry.

Evaluation of population pharmacokinetics in therapeutic trials. IV. Application to postmarketing surveillance

C. DeVane, E. Antal, Thaddeus H Grasela, 1993, Clinical pharmacology and therapy.

Spread-sheet analysis in pharmacokinetic simulations

S. Curry, C. DeVane, Casey Laizure, 1986 .

P-selectin in major depression: preliminary findings with venlafaxine treatment.

J. Sinacore, J. Piletz, C. DeVane, 2010 .

Lack of urinary side‐effects with nefazodone as compared to other newer antidepressants

H. Upadhyaya, C. DeVane, 1998 .

Concentrations of imipramine and its metabolites during enuresis therapy.

C. DeVane, W. Sawyer, R. Walker, 1984, Pediatric pharmacology.

Nefazodone in diabetic neuropathy: response and biology.

P. Goodnick, C. DeVane, A. Kumar, 2000, Psychosomatic medicine.

An Evaluation of Risperidone Drug Interactions

C. Nemeroff, C. DeVane, 2001, Journal of clinical psychopharmacology.

An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram

S. Montgomery, C. DeVane, H. Liston, 2000, International clinical psychopharmacology.

Sertraline in diabetic neuropathy: response and biology.

P. Goodnick, C. DeVane, A. Kumar, 2000, Psychosomatic Medicine.

Commentary 3

C. DeVane, J. Hodgin, 2012 .

Pharmacologic characteristics of ideal antidepressants in the 21st century.

C. DeVane, 2000, The Journal of clinical psychiatry.

Lack of citalopram effect on the pharmacokinetics of cyclosporine.

J. Markowitz, C. DeVane, H. Liston, 2001, Psychosomatics.

Lack of antidepressant-cyclosporine pharmacokinetic interactions.

J. Markowitz, C. DeVane, H. Gill, 1998, Journal of Clinical Psychopharmacology.

Critical Appraisals of Cannabis and Related Compounds in Pharmacotherapy

C. DeVane, 2020, Pharmacotherapy.

Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers

C. DeVane, W. Jusko, M. Savett, 2004, European Journal of Clinical Pharmacology.

Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression.

C. DeVane, E. Kruep, M. Franklin, 2005, The American journal of managed care.

Psychoactive drug interactions with pharmacotherapy for diabetes.

J. Markowitz, C. DeVane, 2002, Psychopharmacology bulletin.

Buspirone: a new type of anxiolytic.

C. DeVane, D. C. Mcleod, C. Dommisse, 1985, Drug Intelligence & Clinical Pharmacy.

Dosage regimen design for cyclic antidepressants: a review of pharmacokinetic methods.

W. Potter, C. DeVane, M. Rudorfer, 1991, Psychopharmacology bulletin.

Evolutionary trends in the pharmacotherapeutic management of depression.

C. Nemeroff, R. Hirschfeld, D. Dunner, 1994, The Journal of clinical psychiatry.

Avoiding psychotropic drug interactions in the cardiovascular patient.

J. Markowitz, C. DeVane, 2000, Bulletin of the Menninger Clinic.

Common herbal supplements did not produce false-positive results on urine drug screens analyzed by enzyme immunoassay.

J. Donovan, J. Markowitz, C. DeVane, 2004, Journal of analytical toxicology.

Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose.

J. Simpkins, C. DeVane, 1985, Drug metabolism and disposition: the biological fate of chemicals.